Arsenic trioxide / Gli1 Cancer Research Results

ATO, Arsenic trioxide: Click to Expand ⟱

Features:

Arsenic has been known for centuries for its toxic and medicinal properties. Although once infamously used as a poison, ongoing research has repurposed arsenic derivatives for medicinal use.

Arsenic trioxide — Arsenic trioxide (As₂O₃) is an intravenously administered inorganic small-molecule antileukemic agent best known for targeting acute promyelocytic leukemia (APL) biology, where it promotes degradation of the PML–RARα oncoprotein and restores differentiation programs while also engaging oxidative/mitochondrial stress pathways. It is a regulated prescription drug (injectable solution; oncology use). Standard abbreviation(s): ATO. Clinically, it is established therapy for APL (including in combination with all-trans retinoic acid, ATRA/tretinoin) and requires strict cardiac/electrolyte and toxicity monitoring due to potentially fatal QT prolongation/arrhythmia and other boxed-warning risks.

Primary mechanisms (ranked):

PML–RARα oncoprotein damage/degradation with downstream re-formation of PML nuclear bodies, differentiation reprogramming, and loss of leukemia-initiating capacity (APL-centric)
Pro-apoptotic stress signaling (mitochondrial dysfunction, DNA fragmentation phenotype in APL models)
Oxidative stress and redox remodeling with downstream stress-response signaling (context-dependent; contributes to cytotoxicity and/or sensitization)
Metabolic suppression in some solid-tumor models (e.g., glycolysis/LDHA axis inhibition reported in specific contexts; not a primary, label-defined mechanism)

Bioavailability / PK relevance: Delivered IV (standard clinical product). In solution it forms arsenious acid (AsIII), the pharmacologically active species; major circulating metabolites include MMAV and DMAV with longer half-lives and greater accumulation vs AsIII. AsIII shows wide tissue distribution (large Vss). Exposure is regimen-driven (oncology dosing) rather than “nutraceutical-like” oral titration; oral ATO exists in research/region-specific formulations but is not the default reference for labeled TRISENOX use.

In-vitro vs systemic exposure relevance: Many mechanistic findings outside APL (ROS/metabolic axes) are concentration- and model-dependent; do not assume that solid-tumor in-vitro concentrations map cleanly onto clinically tolerated systemic exposure given dose-limiting cardiac and systemic toxicities.

Clinical evidence status: Established, guideline-level therapy in APL with randomized phase 3 evidence supporting ATRA+ATO regimens in low/intermediate-risk APL; also indicated for relapsed/refractory APL. Broader “anti-glycolysis/anti-migration” positioning is preclinical/adjunct-hypothesis level outside APL.

Arsenic trioxide — cancer-relevant mechanistic axes (ranked)

Rank	Pathway / Axis	Cancer Cells	Normal Cells	TSF	Primary Effect	Notes / Interpretation
1	PML–RARα proteostasis and differentiation program	↓ PML–RARα (APL); ↑ differentiation; ↓ self-renewal capacity	Not target-defining in most normal tissues	G	Oncoprotein elimination and differentiation-based disease control	Core, clinically validated axis in APL; most “ATO = drug” value is anchored here.
2	Cardiac electrophysiology constraint	—	↑ QTc risk; ↑ torsade risk (with electrolyte/QT-prolonging co-meds)	P/R	Dose-limiting safety axis	Boxed warning includes QT prolongation/ventricular arrhythmias; mandates ECG + K/Mg management.
3	Apoptosis and DNA fragmentation phenotype	↑ apoptosis (APL models); ↑ DNA fragmentation phenotype	Context-dependent toxicity	R	Cytotoxic stress response	Mechanism is “not completely understood” on label; apoptosis phenotype is consistently described for APL cell models.
4	Mitochondria and bioenergetics	↓ ATP (model-dependent)	Context-dependent mitochondrial toxicity	R	Bioenergetic stress	ATP↓ in cancer/diseased cells; often mechanistically tied to ROS/apoptosis networks rather than a single ETC target.
5	ROS and redox stress (secondary)	↑ ROS (context-dependent); redox-driven signaling shifts	↑ oxidative stress risk (context-dependent)	P/R	Stress amplification and sensitization potential	Frequently invoked in preclinical literature; translation constrained by systemic toxicity and disease context.
6	Core metabolism / glycolysis axis	↓ glycolysis (model-dependent); ↓ lactate production; ↓ LDHA/PGK1/PGM1 (reported in specific models)	↔ / context-dependent	G	Metabolic suppression in select tumor models	glycolysis-related downshifts (solid-tumor paper indexing). Outside APL, treat as hypothesis-level and model-specific.
7	Migration / invasion phenotype	↓ migration/invasion phenotypes (model-dependent)	↔	G	Anti-motility signaling (context-dependent)	reduced tumor cell invasion/migration/proliferation phenotypes; not a label-defined therapeutic claim.
8	Drug resistance and efflux	↑ efflux signatures (model-dependent)	↔	G	Adaptive resistance pressure	efflux ↑ as a resistance axis; clinically, regimen design and monitoring dominate over “efflux targeting.”
9	Clinical Translation Constraint	APL benefit is high; broad solid-tumor translation limited	Systemic toxicity limits exposure	—	Therapeutic window and monitoring burden	Key constraints: QTc prolongation/arrhythmia risk, differentiation syndrome risk, encephalopathy/Wernicke’s risk, hepatic/renal impairment considerations; IV delivery standard for TRISENOX.

TSF legend: P: 0–30 min R: 30 min–3 hr G: >3 hr

Gli1, glioma-associated oncogene homolog 1: Click to Expand ⟱

Source:

Type: HH

Gli family zinc-finger transcription factors; GLI1‐dependent target genes (CyclinD1, Bcl‐2, Foxm1)

Glioma-associated oncogene homolog 1 (GLI1) is a transcription factor that plays a significant role in the Hedgehog signaling pathway, which is crucial for cell growth, differentiation, and tissue patterning during embryonic development.
GLI1 can promote tumor growth and survival by regulating the expression of genes involved in cell proliferation, apoptosis, and angiogenesis. Its overexpression has been associated with aggressive tumor behavior and poor prognosis in several cancer types.
ts overexpression is often associated with aggressive tumor behavior, poor prognosis, and resistance to therapy

Scientific Papers found: Click to Expand⟱

7300-

GlaB,

ATO,

Targeting GLI1 and GLI2 with small molecule inhibitors to suppress GLI-dependent transcription and tumor growth

in-vitro,

Var,

Gli↓, HH↓, Gli1↓, BioAv↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Gli↓, 1, Gli1↓, 1, HH↓, 1,

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,
Total Targets: 4

Pathway results for Effect on Normal Cells:

Total Targets: 0

Scientific Paper Hit Count for: Gli1, glioma-associated oncogene homolog 1

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells